

2025

英文論文

1. 2025 Matsubara T, Hagiwara S, Nishida N, Omaru N, Yoshida A, Yamamoto T, Komeda Y, Takenaka M, **Kudo M**: Observational pilot study of switching from entecavir to tenofovir alafenamide in patients with chronic hepatitis B. **Sci Rep** 15:869, 2025. (IF=3.800)
2. 2025 Rubin D, Allegretti JR, Panés J, Shipitofsky N, Yarandi SS, Huang KHG, Germinaro M, Wilson R, Zhang H, Johanns J, Feagan BG, Hisamatsu T, Lichtenstein GR, Bressler B, Peyrin-Biroulet L, Sands BE, Dignass A, **Kudo M**, QUASAR Study Group: Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies. **Lancet** 405:33-49, 2025. (IF=98.400)
3. 2025 Furuse J, Izumi N, Motomura K, Inaba Y, Katamura Y, Kondo Y, Yabushita K, Matsuoka T, Motoyoshi K, **Kudo M**: Long-term survival of patients with unresectable hepatocellular carcinoma treated with lenvatinib in real-world clinical practice. **Cancers** 17:479, 2025. <https://doi.org/10.3390/cancers17030479> (IF=4.500)
4. 2025 Naganuma A, Kakizaki S, Hiraoka A, Tada T, Hatanaka T, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Toyoda H, Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Hirooka M, Yata Y, Ohama H, Kuroda H, Matono T, Aoki T, Kanayama Y, Tanaka K, Tada F, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, **Kudo M**, Kumada T: Evaluation of treatment outcomes using dNLR and GNRI in combination therapy with atezolizumab and bevacizumab for hepatocellular carcinoma. **Cancer Med** 14:e70618, 2025. doi: 10.1002/cam4.70618. (IF=2.900)
5. 2025 Sangro B, **Kudo M**, Erinjeri JP, Qin S, Ren Z, Chan SL, Arai Y,

2025

英文論文

- Heo J, Mai A, Escobar J, Chuken YAL, Yoon JH, Tak WY, Breder VV, Suttichaimongkol T, Bouattour M, Lin SM, Peron JM, Nguyen QT, Yan L, Chiu CF, Santos FA, Veluvolu A, Thungappa SC, Matos M, Żotkiewicz M, Udoeye SI, Kurland JF, Cohen GJ, Lension R, on behalf of the EMERALD-1 Investigators: Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study. **Lancet** 405:216-232, 2025. (IF=98.400)
6. 2025 **Kudo M**[†], Ren Z[†], Guo Y, Han G, Lin H, Zheng J, Ogasawara S, Kim JH, Zhao H, Li C, Madccoff DC, Ghobrial RM, Kawaoka T, Gerolami R, Ikeda M, Kumada H, El-Khoueiry AB, Vogel A, Peng X, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS[†], Llovet JM[†], and the LEAP-012 investigators: Transarterial chemoembolisation combined with Lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study. **Lancet** 405:203-215, 2025. (†Shard 1st authors) (IF=98.400)
7. 2025 Morimoto-Ishikawa D, Hyodo T, Komeda Y, Fukushima H, Itoh M, Ueda Y, **Kudo M**, Saito S, Ishii K: Quantitative evaluation of noncontrast magnetic resonance enterography for active inflammation in crohn disease using native T1 and T2 mapping. **J Comput Assist Tomogr** 49:1-8, 2025. (IF=1.000)
8. 2025 Lau G, Abou-Alfa GK, Cheng AL, Sukeepaisarnjaroen W, Dao TV, Kang YK, Thungappa SC, **Kudo M**, Sangro B, Kelley RK, Furuse J, Park JW, Sunpaweravong P, Fasolo A, Yau T, Kawaoka T, Azevedo S, Reig M, Assenat E, Yarchoan M, He AR, Makowsky M, Gupta C, Negro A, Chan SL: Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. **J Hepatol** 82:258-267, 2025. (IF=26.800)

2025

英文論文

9. 2025 Kawano K, Takenaka M, Kawano R, Kagoshige D, Mine K, Nishi K, **Kudo M**: A novel clip with mantis-like claws combined with the over-the-scope clip for fistula closure. **Endoscopy** 57:E130-E132, 2025. (IF=11.500)
10. 2025 Kodama Y, Ueshima K, Moriguchi M, Inaba Y, Yamashita T, Iwamoto H, Ueno M, Ogasawara S, Kuzuya T, Kodama T, Sato Y, Tada T, Tsuchiya K, Nishiofuku H, Yamakado K, Sone M, Ikeda M, Takehara T, Hamano T, **Kudo M***: Protocol of the IMPACT study: randomized, multicenter, phase 3 study evaluating the efficacy of immunotherapy (Atezolizumab) plus anti-VEGF therapy (Bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma. **BMC Cancer** 25:434, 2025. doi: 10.1186/s12885-025-13648-5. (IF=3.400)
11. 2025 Minaga K, Watanabe T, Hara A, Yoshikawa T, Kamata K, **Kudo M**: Gut microbiota involved in the immunopathogenesis of autoimmune pancreatitis. **Gut Liver** 19:171-176, 2025. (IF=3.400)
12. 2025 Hara A, Watanabe T, Minaga K, Kamata K, Strober W, **Kudo M**: Sequential activation of conventional and plasmacytoid dendritic cells in autoimmune pancreatitis and systemic lupus erythematosus: similarities and dissimilarities. **Front Immunol** 16:1554492, 2025. (IF=5.700)
13. 2025 Trevisani F, Vitale A, Colli A, **Kudo M**, Kulik L, Park JW, Pinato DJ, Cillo U: Evidence-based failure of stage hierarchy therapeutic approach to HCC. **J Hepatol**, 2025 (Epub ahead of print). (IF=26.800)
14. 2025 Celsa C, Cabibbo G, Fulgenzi CAM, Battaglia S, Enea M, Scheiner B, D'Alessio A, Manfredi GF, Stefanini B, Nishida N, Galle PR, Schulze K, Wege H, Ciccia R, Hsu WF, Vivaldi C,

2025

英文論文

- Wietharn B, Lin RP, Pirozzi A, Pressiani T, Dalbeni A, Natola LA, Auriemma A, Rigamonti C, Burlone M, Parisi A, Huang YH, Lee PC, Ang C, Marron TU, Pinter M, Cheon J, Phen S, Singal AG, Gampa A, Pillai A, Roehlen N, Thimme R, Vogel A, Soror N, Ulahannan S, Sharma R, Sacerdoti D, Pirisi M, Rimassa L, Lin CY, Saeed A, Masi G, Schönlein M, von Felden J, **Kudo M**, Cortellini A, Chon HJ, Cammà C, Pinato DJ: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment. **Hepatology**, 2025 (Epub ahead of print). (IF=12.900)
15. 2025 Aoki T, Nishida N, Minami Y, **Kudo M***: The impact of normal hepatobiliary cell zonation programs on the phenotypes and functions of primary liver tumors. **Liver Cancer**, 2025 (Epub ahead of print). (IF=11.600)
16. 2025 Persano M, Casadei-Gardini A, Tada T, Suda G, Shimose S, **Kudo M**, Rossari F, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone M, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Soldà C, Sho T, Niizeki T, Nishida N, Steup C, Bruccoleri M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Mascia L, Foti S, Camera S, Piscaglia F, Scartozzi M, Cascinu S, Rimini M: Lenvatinib versus sorafenib second-line therapy in patients with hepatocellular carcinoma progressed to atezolizumab plus bevacizumab: A retrospective real-world study. **Oncology**, 2025 (Epub ahead of print). (IF=2.500)

2025

英文論文

17. 2025 Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ohama H, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Nishikawa H, Imai M, Aoki T, Ochi H, Tada F, Nakamura S, Nakamura Y, Nouse K, Morishita A, Itokawa N, Okubo T, Arai Y, Tsutsui A, Nagano T, Tanaka K, Tanaka H, Koshiyama Y, Kanayama Y, Noritake H, Enomoto H, Kaibori M, Hiasa Y, **Kudo M**, Kumada T, on behalf of the RELPEC Group and HCC 48 Group: Efficacy of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma in immunotherapy era clinical practice. **Hepatol Res**, 2025 (Epub ahead of print). (IF=3.900)
18. 2025 Kurimoto M, Honjo H, Yoshida S, Okai N, Otsuka Y, Masuta Y, Masaki S, Kamata K, Minaga K, Maenishi O, **Kudo M**, Watanabe T: Enlargement of gastric hyperplastic polyps arising from helicobacter heilmannii sensu stricto-infected mucosa after the successful eradication of helicobacter pylori and the long-term use of a proton pump inhibitor. **Intern Med**, 2025 (Epub ahead of print). (IF=1.000)
19. 2025 Okushin K, Tateishi R, Hirakawa S, Tachimori H, Uchino K, Nakagomi R, Yamada T, Nakatsuka T, Minami T, Sato M, Fujishiro M, Hasegawa K, Eguchi Y, Kanto T, Yoshiji H, Izumi N, **Kudo M**, Koike K: Comparable outcomes among etiologies in early-stage hepatocellular carcinoma: An analysis of a nationwide registry in Japan. **Hepatol Res**, 2025 (Epub ahead of print). (IF=3.900)
20. 2025 Scheiner B, Kang B, Balcar L, Radu IP, Reiter FP, Adžić G, Guo J, Gao X, Yuan X, Cheng L, Gorgulho J, Schultheiss M, Peeters F, Huckle F, Khaled NB, Piseddu I, Philipp A, Sinner F, D'Alessio A, Pomej K, Saborowski A, Bathon M, Schwacha-Eipper B, Zarka V, Lampichler K, Nishida N, Lee PC, Krall A, Saeed A, Himmelsbach V, Tesini G, Huang YH, Vivaldi C, Masi G, Vogel

2025

英文論文

- A, Schulze K, Trauner M, Djanani A, Stauber R, **Kudo M**, Parikh ND, Dufour JF, Prejac J, Geier A, Bengsch B, von Felden J, Venerito M, Weinmann A, Radosavljevic MP, Finkelmeier F, Dekervel J, Ji F, Wang HW, Rimassa L, Pinato DJ, Bouattour M, Chon HJ, Pinter M: Outcome and management of patients with hepatocellular carcinoma who achieved complete response to immunotherapy-based systemic therapy. **Hepatology**, 2025 (Epub ahead of print). (IF=12.900)
21. 2025 **Kudo M***, Ikeda M, Aikata H, Numata K, Marusawa H, Hosaka T, Kato N, Kurosaki M, Morimoto M, Yamashita T, Koga H, Masaki T, Yatsuzuka N, Suzuki M, Nagao S, Kaneko S, Kumada H: First-line lenvatinib plus pembrolizumab for hepatocellular carcinoma: Post hoc analysis of Japanese patients from the phase 3 LEAP-002 trial. **Liver Cancer**, 2025 (Epub ahead of print). (IF=11.600)
22. 2025 Motono T, Tada T, Kumada T, Hiraoka A, Hiroka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Nishikawa H, Tanaka K, Tsuji K, Ishikawa T, Tajiri K, Koshiyama Y, Toyoda H, Tada F, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Nishimura T, Imai M, Kosaka H, Naganuma A, Aoki T, Kuroda H, Yata Y, Nakamura Y, Yoshida O, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, **Kudo M**, on behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group, the Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group: Survival outcomes associated with radiological progressive disease subtypes in patients with atezolizumab and bevacizumab–treated HCC. **J Gastroen Hepatol**, 2025 (Epub ahead of print). (IF=3.700)
23. 2025 Morita M, Takita M, Nishida N, **Kudo M**: Giant sister Mary Joseph's nodule in hepatocellular carcinoma. **Am J Gastroenterol**, 2025 (Epub ahead of print). (IF=8.500)
24. 2025 Kim YJ, Merle P, Finn RS, **Kudo M**, Klumpen HJ, Lim HY, Ikeda

2025

英文論文

- M, Granito A, Masi G, Gerolami R, ChoSB, Hsu CH, Huang YH, Jeng LB, Kim DY, Lin SM, Pinter M, Shao G, Kato N, Kurosaki M, Numata K, Kuo KK, Mao Y, Lin YJ, Zhu K, Twumasi-Ankrah P, Khan J, Awan M, Ozgurdal K, Qin S: Regorafenib for hepatocellular carcinoma in real-world practice (REFINE): a prospective, observational study. **Liver Cancer**, 2025 (Epub ahead of print). (IF=11.600)
25. 2025 **Kudo M***: Lenvatinib plus pembrolizumab combined with transarterial chemoembolization in intermediate-stage hepatocellular carcinoma. **Liver Cancer**, 2025 (Epub ahead of print). (IF=11.600)
26. 2025 Finn RS, Gu K, Chen X, Merle P, Lee KH, Bouattour M, Cao P, Wang W, Cheng AL, Zhou L, Lim HY, **Kudo M**, Pan Y, Chang TT, Edeline J, Li W, Yang P, Li C, Li J, Siegel AB, Qin S: Second-line pembrolizumab for advanced HCC: meta-analysis of the phase 3 KEYNOTE-240 and KEYNOTE-394 studies. **JHEP Reports**, 2025 (Epub ahead of print). (IF=9.500)
27. 2025 Hiraoka A, **Kudo M**, Tada T, Hatanaka T, Kakizaki S, Kariyama K, Ohama H, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, Toyoda H, Matono T, Yata Y, Ogawa C, Naganuma A, Tani J, Atsukawa M, Nishimura T, Tajiri K, Kawata K, Kosaka H, Kuroda H, Hirooka M, Nishikawa H, Tada F, Nakamura S, Kanayama Y, Nouse K, Tanaka H, Tanaka K, Imai M, Tsutsui A, Nagano T, Aoki T, Koshiyama Y, Morishita A, Itokawa N, Okubo T, Arai T, Fukunishi S, Noritake H, Nakamura Y, Yoshida O, Enomoto H, Kaibori M, Hiasa Y, Kumada T: The current status of tumor markers as biomarkers in the era of immunotherapy for hepatocellular carcinoma: alpha-fetoprotein alone is not sufficient. **Oncology**, 2025 (Epub ahead of print). (IF=2.500)
28. 2025 Naganuma A, Kakizaki S, Hatanaka T, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Toyoda

2025

英文論文

- H, Koshiyama Y, Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Matsui K, Yata Y, Tanaka H, Ohama H, Kuroda H, Matono T, Aoki T, Ochi H, Imai M, Nakamura S, Kanayama Y, Tanaka K, Tada F, Yoshida O, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Enomoto H, Kaibori M, Hiasa Y, **Kudo M**, Kumada T: Impact of time-of-day atezolizumab plus bevacizumab combination therapy infusion for unresectable hepatocellular carcinoma: A retrospective multicenter study. **Hepatol Res**, 2025 (Epub ahead of print). (IF=3.900)
29. 2025 Yamao K, Takenaka M, Yoshida A, Yamazaki T, Omoto S, Minaga K, Kamata K, Takada Y, Uetsuki K, Iida T, Mizutani Y, Ishikawa T, Kawashima H, **Kudo M**: Concealed pancreatic cancer in acute pancreatitis: Early MRCP and EUS surveillance improves prognosis and identifies high-risk patients. **Pancreatology**, 2025 (Epub ahead of print). (IF=2.800)
30. 2025 Aoki T, Nishida N, Kurebayashi Y, Sakai K, Fujiwara N, Tsurusaki M, Hanaoka K, Morita M, Chishina H, Takita M, Hagiwara S, Ida H, Ueshima K, Minami Y, Takebe A, Murase T, Kamei K, Nakai T, Mastumoto I, Nishio K, **Kudo M***: Molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathway. **Clin Mol Hepatol**, 2025 (Epub ahead of print). (IF=14.000)
31. 2025 Aoki T, **Kudo M***, Nishida N, Ueshima K, Tsuchiya K, Tada T, Morita M, Chishina H, Takita M, Hagiwara S, Ida H, Minami Y, Kuroda H, Nakamura N, Hiraoka A, Tomonari T, Tani J, Naganuma A, Kakizaki S, Ogawa C, Hatanaka T, Ishikawa T, Kawata K, Takebe A, Matsumoto I, Hidaka M, Kurosaki M, Kumada T, Izumi N: Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study. **J Gastroenterol**, 2025 (Epub ahead of print). (IF=6.900)